SMaRT Replacement Therapy - Oragenics

Drug Profile

SMaRT Replacement Therapy - Oragenics

Alternative Names: A2JM

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Oragenics Inc
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Dental caries

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Dental-caries(In volunteers) in USA (Topical)
  • 30 Mar 2011 Oragenics initiates enrolment in a phase I trial in Healthy volunteers in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top